TipRanks
Ardelyx (DE:41X)
FRANKFURT:41X
Germany Market
41X
Ardelyx
RESEARCH TOOLSreports

Ardelyx (41X) Stock Forecast & Price Target

8 Followers
See the Price Targets and Ratings of:

41X Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Ardelyx
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

41X Stock 12 Month Forecast

Average Price Target

€11.86
▲(264.98% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is €11.86 with a high forecast of €15.67 and a low forecast of €7.84. The average price target represents a 264.98% change from the last price of €3.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","9":"€9","16":"€16","5.5":"€5.5","12.5":"€12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.67087002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€15.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.86197800125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.83543501,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,4.168528463076923,5.127056926153847,6.085585389230769,7.044113852307692,8.002642315384616,8.96117077846154,9.919699241538463,10.878227704615385,11.836756167692307,12.795284630769231,13.753813093846155,14.712341556923079,{"y":15.67087002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,3.8755367693269234,4.541073538653846,5.206610307980769,5.872147077307693,6.537683846634616,7.2032206159615395,7.868757385288462,8.534294154615385,9.199830923942308,9.865367693269231,10.530904462596155,11.196441231923078,{"y":11.86197800125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.21,3.565802693076923,3.9216053861538462,4.277408079230769,4.6332107723076925,4.989013465384615,5.344816158461539,5.7006188515384615,6.056421544615384,6.412224237692308,6.768026930769231,7.123829623846154,7.479632316923077,{"y":7.83543501,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.354,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.619,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.959,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.844,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.298,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.442,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.425,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.325,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€15.67Average Price Target€11.86Lowest Price Target€7.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on DE:41X
Laura Chico
Wedbush
Wedbush
€7.84
Buy
141.09%
Upside
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)
Piper Sandler Analyst forecast on DE:41X
Allison Bratzel
Piper Sandler
Piper Sandler
€13.93→€13.06
Buy
301.82%
Upside
Reiterated
08/17/26
Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler
Citi Analyst forecast on DE:41X
Yigal Nochomovitz
Citi
Citi
€12.19→€9.58
Buy
194.67%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on DE:41X
Caroline Palomeque
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€13.93
Buy
328.60%
Upside
Reiterated
08/10/26
Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)
H.C. Wainwright Analyst forecast on DE:41X
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
€15.67
Buy
382.18%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on DE:41X
Christopher Raymond
Raymond James
Raymond James
€16.54→€13.06
Buy
301.82%
Upside
Reiterated
08/07/26
Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James
TD Cowen Analyst forecast on DE:41X
Joseph Thome
TD Cowen
TD Cowen
€11.32→€8.71
Buy
167.88%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Jefferies Analyst forecast on DE:41X
Dennis Ding
Jefferies
Jefferies
€13.06
Buy
301.82%
Upside
Reiterated
06/26/26
Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'
BTIG Analyst forecast on DE:41X
Julian Harrison
BTIG
BTIG
€14.8
Buy
355.39%
Upside
Reiterated
02/20/26
Ardelyx (ARDX) Receives a Buy from BTIG
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on DE:41X
Laura Chico
Wedbush
Wedbush
€7.84
Buy
141.09%
Upside
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)
Piper Sandler Analyst forecast on DE:41X
Allison Bratzel
Piper Sandler
Piper Sandler
€13.93→€13.06
Buy
301.82%
Upside
Reiterated
08/17/26
Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler
Citi Analyst forecast on DE:41X
Yigal Nochomovitz
Citi
Citi
€12.19→€9.58
Buy
194.67%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on DE:41X
Caroline Palomeque
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€13.93
Buy
328.60%
Upside
Reiterated
08/10/26
Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)
H.C. Wainwright Analyst forecast on DE:41X
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
€15.67
Buy
382.18%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on DE:41X
Christopher Raymond
Raymond James
Raymond James
€16.54→€13.06
Buy
301.82%
Upside
Reiterated
08/07/26
Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James
TD Cowen Analyst forecast on DE:41X
Joseph Thome
TD Cowen
TD Cowen
€11.32→€8.71
Buy
167.88%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Jefferies Analyst forecast on DE:41X
Dennis Ding
Jefferies
Jefferies
€13.06
Buy
301.82%
Upside
Reiterated
06/26/26
Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'
BTIG Analyst forecast on DE:41X
Julian Harrison
BTIG
BTIG
€14.8
Buy
355.39%
Upside
Reiterated
02/20/26
Ardelyx (ARDX) Receives a Buy from BTIG
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
ZVRAZevra Therapeutics
IMUXImmunic
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

3 Months
Yigal NochomovitzCiti
Success Rate
8/16 ratings generated profit
50%
Average Return
+25.06%
Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +25.06% per trade.
1 Year
Christopher RaymondRaymond James
Success Rate
8/17 ratings generated profit
47%
Average Return
+21.52%
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +21.52% per trade.
2 Years
Christopher RaymondRaymond James
Success Rate
7/17 ratings generated profit
41%
Average Return
+9.51%
Copying Christopher Raymond's trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +9.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

41X Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
6
8
6
10
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
8
6
10
8
In the current month, 41X has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 41X average Analyst price target in the past 3 months is 11.86.
Each month's total comprises the sum of three months' worth of ratings.

41X Financial Forecast

41X Earnings Forecast

Next quarter’s earnings estimate for 41X is -€0.01 with a range of -€0.05 to €0.02. The previous quarter’s EPS was -€0.06. 41X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.
Next quarter’s earnings estimate for 41X is -€0.01 with a range of -€0.05 to €0.02. The previous quarter’s EPS was -€0.06. 41X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Sales Forecast

Next quarter’s sales forecast for 41X is €111.09M with a range of €102.83M to €115.63M. The previous quarter’s sales results were €103.92M. 41X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.
Next quarter’s sales forecast for 41X is €111.09M with a range of €102.83M to €115.63M. The previous quarter’s sales results were €103.92M. 41X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Stock Forecast FAQ

What is DE:41X’s average 12-month price target, according to analysts?
Based on analyst ratings, Ardelyx’s 12-month average price target is 11.86.
    What is DE:41X’s upside potential, based on the analysts’ average price target?
    Ardelyx has 264.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ardelyx a Buy, Sell or Hold?
          Ardelyx has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ardelyx’s share price target?
            The average share price target for Ardelyx is 11.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €15.67 ,and the lowest forecast is €7.84. The average share price target represents 264.98% Increase from the current price of €3.25.
              What do analysts say about Ardelyx?
              Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Ardelyx?
                To buy shares of DE:41X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.